VXRT Stock Price: Vaxart Inc gains as novel coronavirus vaccines begin to receive approval
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:VXRT adds 0.67% on Thursday amidst a mostly flat trading session in the global markets.
- Investors await news on Vaxart’s latest clinical studies for its COVID-19 treatment candidate.
- Logistical issues and allergic reactions may open the door for Vaxart’s unique treatment.
NASDAQ:VXRT was little changed on Thursday despite the first official FDA approvals for the COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Vaxart added 0.67% during Thursday’s trading session as the stock closed the day at $7.46, which represents a gain of over 80% during the last month as investors begin to speculate on the next group of companies who could receive regulatory approval.
The results of Vacart’s Phase 1 clinical studies for its treatment VXA-CoV2-1 should be ready by January and Phase 2 should follow closely after if the findings are positive. What sets Vaxart’s treatment candidate apart that investors are so excited about? It is an oral pill and not a shot, which of course makes storage and shipment around the world a logistical dream compared to vaccines that need to be stored in below-freezing containers. The oral pill could also have fewer side effects as the first round of COVID-19 vaccine shots have already returned some allergic reactions. Manufacturing of pills should be much simpler than the production of vaccine samples as well, meaning potential lower costs and wider availability to all corners of the world.
Vaxart stock news
Needless to say, the stock has had a pretty good run since entering the race for a COVID-19 treatment earlier this year. Shares have returned over 2,300% and at a reasonable price level, investors could look to Vaxart as an appealing play in the next wave of COVID-19 treatment options. Investing in biotechs can be risky, but investors should keep a close eye on the clinical trial results as the low price of this stock could lead to some massive gains down the road.
- NASDAQ:VXRT adds 0.67% on Thursday amidst a mostly flat trading session in the global markets.
- Investors await news on Vaxart’s latest clinical studies for its COVID-19 treatment candidate.
- Logistical issues and allergic reactions may open the door for Vaxart’s unique treatment.
NASDAQ:VXRT was little changed on Thursday despite the first official FDA approvals for the COVID-19 vaccine candidate from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Vaxart added 0.67% during Thursday’s trading session as the stock closed the day at $7.46, which represents a gain of over 80% during the last month as investors begin to speculate on the next group of companies who could receive regulatory approval.
The results of Vacart’s Phase 1 clinical studies for its treatment VXA-CoV2-1 should be ready by January and Phase 2 should follow closely after if the findings are positive. What sets Vaxart’s treatment candidate apart that investors are so excited about? It is an oral pill and not a shot, which of course makes storage and shipment around the world a logistical dream compared to vaccines that need to be stored in below-freezing containers. The oral pill could also have fewer side effects as the first round of COVID-19 vaccine shots have already returned some allergic reactions. Manufacturing of pills should be much simpler than the production of vaccine samples as well, meaning potential lower costs and wider availability to all corners of the world.
Vaxart stock news
Needless to say, the stock has had a pretty good run since entering the race for a COVID-19 treatment earlier this year. Shares have returned over 2,300% and at a reasonable price level, investors could look to Vaxart as an appealing play in the next wave of COVID-19 treatment options. Investing in biotechs can be risky, but investors should keep a close eye on the clinical trial results as the low price of this stock could lead to some massive gains down the road.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.